Clinical Trials on Pure Red-Cell Aplasia

Total 3905 results

Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Filgrastim to Stimulate Peripheral Stem Cells in Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
AEterna Zentaris

Completed

AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm
Institut Paoli-Calmettes

Completed

Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment

Multiple Myeloma and Plasma Cell Neoplasm

France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Hoag Memorial Hospital Presbyterian
Cancer Biotherapy Research Group

Withdrawn

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
University Hospital, Lille

Recruiting

Impact of Supportive Care on the Experience of Hospitalization of Patients Staying in the Protected Area of the Department of Blood Diseases (ASTERIA)

Acute Leukemia | Aplasia | Hematopoietic Stem Cell Transplantation (SCT)

France
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia (HAPLO-EMPTY)

Refractory Idiopathic Aplastic Anemia | Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation
NCIC Clinical Trials Group
National Cancer Institute (NCI); Eastern Cooperative Oncology Group

Completed

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); European Organisation for Research and Treatment... and other collaborators

Completed

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States, Canada
Roswell Park Cancer Institute

Completed

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
NCIC Clinical Trials Group

Completed

Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

Canada, United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
UNC Lineberger Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Millennium Pharmaceuticals, Inc.; Ortho Biotech, Inc.

Terminated

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Study of DNA Samples From Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide

Multiple Myeloma and Plasma Cell Neoplasm
University of Miami

Withdrawn

Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Cancer Trials Ireland

Completed

PAD. ICORG 05-01, V11

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom, Ireland
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Maryland Greenebaum Cancer Center
National Cancer Institute (NCI)

Completed

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Genta Incorporated

Completed

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

Multiple Myeloma and Plasma Cell Neoplasm

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Riverside Haematology Group

Unknown

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United Kingdom
Oncotherapeutics

Completed

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
The Cleveland Clinic

Completed

Rituximab in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fox Chase Cancer Center
National Cancer Institute (NCI)

Completed

SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Tennessee

Completed

Interferon Alfa Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Antithymocyte Globulin in Treating Patients Undergoing Stem Cell Transplant for Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States, Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic
National Cancer Institute (NCI)

Completed

High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse

Multiple Myeloma and Plasma Cell Neoplasm

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Melphalan and Busulfan Followed By Donor Peripheral Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
University of California, San Francisco
National Cancer Institute (NCI)

Unknown

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Lymphoma | Kidney Cancer | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

United States
Senesco Technologies, Inc.

Unknown

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Multiple Myeloma | Plasma Cell Leukemia | Multiple Myeloma in Relapse | Mantle Cell Lymphoma in Relapse | Diffuse Large B Cell Lymphoma in Relapse | Other B Cell Lymphoma in Relapse

United States, South Africa
Siriraj Hospital

Not yet recruiting

Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing (genetics MM)

Plasma Cell Disorder

Clinical Trials on Pure Red-Cell Aplasia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations